- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Gavreto, FDA Approved for Treatment of Metastatic RET Fusion-Positive NSCLC, Available at Biologics by McKesson
Gavreto was granted accelerated approval by the FDA on September 4, 2020, for the treatment of adult patients with metastatic RET fusion-positive non–small cell lung cancer (NSCLC).
CARY, N.C.—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Blueprint Medicines as a specialty pharmacy provider for Gavreto (pralsetinib) for the treatment of adult patients with metastatic RET fusion-positive non–small cell lung cancer (NSCLC) as detected by an FDA-approved test.
Gavreto, which was granted accelerated approval by the FDA on September 4, 2020, was specifically designed to inhibit RET alterations. RET fusions are oncogenic drivers for multiple solid tumor types. This drug was given priority review by the FDA, which is granted to drugs that are expected to have a large impact on a disease’s treatment.
“Gavreto gives patients a new RET inhibitor option for treating their RET-driven metastatic NSCLC,” said Allison Kinnarney, director of Clinical Programs with Biologics.
AI in Health Care: Balancing Governance, Innovation, and Trust
September 2nd 2025In this conversation with Reuben Daniel, associate vice president of artificial intelligence at UPMC Health Plan, we dive into how UPMC Health Plan builds trust with providers and members, discuss challenges of scaling AI effectively, and hear about concrete examples of AI's positive impact.
Listen
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
